ArticleScientific reports2019
The oncolytic adenovirus VCN-01 promotes anti-tumor effect in primitive neuroectodermal tumor models.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Cellular and Immunotherapy for Pediatric Brain Tumors: A Primer.Current oncology (Toronto, Ont.) · 2026Review
- Integrating oncolytic adenoviruses into combination cancer therapy: Mechanisms, advances and clinical outlook.Clinical and translational medicine · 2026Review
- Potency-enhancing mutations in E3-19K and i-leader increase the cytolytic activity of the PH20/Molecular therapy. Oncology · 2026Article
- Current use of pre-clinical models for evaluation of human adenovirus-based cancer therapeutics.Molecular therapy. Oncology · 2026Review
- The emerging field of viroimmunotherapy for pediatric brain tumors.Neuro-oncology · 2024Review
- Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy.Nature protocols · 2024Review
- Retinoblastoma: An update on genetic origin, classification, conventional to next-generation treatment strategies.Heliyon · 2024Review
- Extracellular matrix re-normalization to improve cold tumor penetration by oncolytic viruses.Frontiers in immunology · 2024Review
- Tumor-Homing of Mesenchymal Stem Cells Infected with Oncolytic Virus in a Canine Patient.Veterinary sciences · 2022Article
- Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality.Frontiers in immunology · 2022Review
- Hyaluronidase expression within tumors increases virotherapy efficacy and T cell accumulation.Molecular therapy oncolytics · 2021Article
- Immunomodulatory Arming Factors-The Current Paradigm for Oncolytic Vectors Relies on Immune Stimulating Molecules.International journal of molecular sciences · 2021Review
- Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors.International journal of molecular sciences · 2020Review
- [Clinical effect of surgery combined with chemotherapy and radiotherapy in children with central primitive neuroectodermal tumor and prognostic analysis].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2020Article
- Effect of Transgene Location, Transcriptional Control Elements and Transgene Features in Armed Oncolytic Adenoviruses.Cancers · 2020Review
- Oncolytic virotherapies for pediatric tumors.Expert opinion on biological therapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Last advances in the treatment of pediatric tumors has led to an increase of survival rates of children affected by primitive neuroectodermal tumors, however, still a significant amount of the patients do not overcome the disease. In addition, the survivors might suffer from severe side effects caused by the current standard treatments. Oncolytic virotherapy has emerged in the last years as a promising alternative for the treatment of solid tumors. In this work, we study the anti-tumor effect mediated by the oncolytic adenovirus VCN-01 in CNS-PNET models. VCN-01 is able to infect and replicate in PNET cell cultures, leading to a cytotoxicity and immunogenic cell death. In vivo, VCN-01 increased significantly the median survival of mice and led to long-term survivors in two orthotopic models of PNETs. In summary, these results underscore the therapeutic effect of VCN-01 for rare pediatric cancers such as PNETs, and warrants further exploration on the use of this virus to treat them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.